Medicine from Biologics Experts

Experience that
can’t be replicated

Amgen Biosimilars are backed by our four decades of experience in the research, development, manufacturing, and supply of innovator biologics.

Your source for biosimilars information.
Learn more

We are biologics
experts

At Amgen, we are proven innovators in a field that’s constantly accelerating. We are inspired every day to engineer robust and differentiated therapeutics.

18 US FDA approval since 1980,
and 4 biosimilar medicines

13EMA approval since 2001,
and 2 biosimilar medicines

31innovator products in various stages of clinical development

10products in
our portfolio of biosimilar medicines*

As of August 7, 2019 *Numbers shown are global numbers

HERITAGE

With four decades of biologics experience, we are now one of the largest independent biotechnology companies.

EXPERTISE

We are end-to-end biologics experts, with an extensive experience in all phases, from development to manufacturing, aiming to deliver a reliable supply.

COMMITMENT

At the heart of our commitment to biosimilars is our mission to serve each and every patient.

OUR PRODUCTS

We have a portfolio of 10 biosimilar medicines as of August 2019, including potential treatments for cancer and chronic inflammatory diseases.

SUPPORT

We provide extensive services to support your biologics experience, making sure that every patient who needs our medicines can access them.

HK-09628-AMGEN-2022-Dec Date of Approval: Dec 2022

Experience that can’t be replicated Amgen Biosimilars are backed by our four decades of experience in the research, development, manufacturing, and supply of innovator biologics. Your source for biosimilars information. Learn more

Experience that can’t be replicated

We are biologics experts